Explore early data from the ACTS program that reveal the volume and types of patient-reported barriers to cancer care and ...
In a new ACT video interview, Shanthi Sivendran, MD, MSCR, MBA, senior vice president for cancer care support at the American ...
A structured data ownership model—rooted in ICH GCP principles, supported by MHRA and FDA interpretations, and documented in validated system specifications—will enable sponsors to maintain compliance ...
Learn why combining AI-enabled trial matching with transportation, lodging, and financial assistance is essential to turning ...
Review the performance, engagement, and satisfaction metrics sponsors and CROs should track to determine whether operational ...
If we can use AI or AI agents to automate those workflows, you can still run the same process, particularly as it relates to ...
In today’s ACT Brief, we cover the FDA approval of oral Wegovy based on Phase III OASIS 4 results, recap the most-read ...
In today’s ACT Brief, we examine why fragmented data systems continue to slow life sciences research, review how sponsor ...
Funding uncertainty, legal and political pressures, trade policy shifts, site collaboration strategies, and leadership perspectives were central themes across Applied Clinical Trials’ most-watched ...
Wegovy pill, the first oral GLP-1 for weight loss, is FDA-approved for reducing cardiovascular risks in adults. Phase III OASIS 4 trial showed 16.6% mean weight loss with oral semaglutide, ...
Persistent recruitment delays, high dropout rates, and missed timelines continue to slow global clinical trials, while data show that sub-Saharan Africa offers a largely untapped opportunity with ...
Generative AI adoption, regulatory scrutiny, DEI policy shifts, real-world evidence, and rare disease economics emerged as key themes across these most-read Applied Clinical Trials articles shaping ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback